Vivus Inc., of Mountain View, Calif., presented several posters at the European Congress on Obesity in Istanbul, Turkey, including data that showed Qnexa (phentermine/topiramate) reduced progression to Type II diabetes and improved glycemic status in patients defined as prediabetics at baseline. In the prediabetic population from the CONQUER study, significantly more Qnexa-treated patients achieved normal blood sugar levels (p = 0.0016) and significantly more patients in the placebo arm progressed to Type II diabetes (p = 0.0253). Qnexa was rejected by the FDA last year, but Vivus plans to resubmit a new drug application in the fourth quarter of this year.